Synthesis and study of 5'-ester prodrugs of N6-cyclopentyladenosine, a selective A1 receptor agonist

Pharm Res. 2001 Apr;18(4):531-6. doi: 10.1023/a:1011018730459.

Abstract

Purpose: A series of 5'-esters of N6-cyclopentyladenosine (CPA) were prepared with the aim to improve stability and bioavailability of selective A1 agonists. Log P values, stability, affinity, and activity toward human adenosine A1 receptors were evaluated.

Methods: An appropriate synthetic procedure was adopted to avoid concomitant deamination at position 6. Log P values were obtained by the Mixxor system. The stability of CPA and its 5'-ester was evaluated in human plasma and whole blood and analyzed with high-performance liquid chromatography. The affinities to human A1 receptor expressed by N6-cyclohexyladenosine cells were obtained by binding experiments. The activities were evaluated by measurements of the inhibition of forskolin stimulated 3'-5'-cyclic adenosine monophosphate, performing competitive binding assays.

Results: All prodrugs were more lipophilic than CPA, and their hydrolysis, in whole blood and in plasma, was found related, respectively, to the length and hindrance of 5'-substituents. Affinity and activity values indicated a very weak interaction toward adenosine A1 receptor of the intact prodrugs.

Conclusions: We propose 5'-esters of CPA, characterized by suitable lipophilicity and elevated degree of stability in physiological fluids, as possible candidates for CPA prodrugs.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine / analogs & derivatives*
  • Adenosine / chemical synthesis*
  • Adenosine / pharmacokinetics*
  • Animals
  • Dose-Response Relationship, Drug
  • Prodrugs / chemical synthesis*
  • Prodrugs / pharmacokinetics*
  • Purinergic P1 Receptor Agonists*
  • Rats
  • Receptors, Purinergic P1 / metabolism

Substances

  • Prodrugs
  • Purinergic P1 Receptor Agonists
  • Receptors, Purinergic P1
  • N(6)-cyclopentyladenosine
  • Adenosine